Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen

[1]  A. Iliadis,et al.  Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile , 2009, Cancer Chemotherapy and Pharmacology.

[2]  B. Lembersky,et al.  Phase II study of bevacizumab (BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox) on an every-2-week schedule for patients (Pts) with untreated advanced colorectal cancer (CRC) , 2008 .

[3]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Thomas Gruenberger,et al.  Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Cassidy.  Capecitabine plus oxaliplatin in metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Mayer.  Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Greil,et al.  Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Smith,et al.  Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC) , 2007 .

[9]  H. Lenz,et al.  Capecitabine: the new generation of fluoropyrimidines in colorectal cancer , 2004, Expert review of anticancer therapy.

[10]  L. Zufía,et al.  Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Scheithauer,et al.  Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Blesch,et al.  Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. , 2003, British journal of clinical pharmacology.

[14]  Deo Kumar Srivastava,et al.  Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Scheithauer,et al.  Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Twelves.  Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. , 2002, European journal of cancer.

[17]  B. Reigner,et al.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[19]  H. Ishitsuka,et al.  Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. , 1983, Chemical & pharmaceutical bulletin.

[20]  S. Guichard,et al.  Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. , 2008, European journal of cancer.

[21]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[22]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.